NO305125B1 - Farmas°ytiske forbindelser - Google Patents

Farmas°ytiske forbindelser

Info

Publication number
NO305125B1
NO305125B1 NO931917A NO931917A NO305125B1 NO 305125 B1 NO305125 B1 NO 305125B1 NO 931917 A NO931917 A NO 931917A NO 931917 A NO931917 A NO 931917A NO 305125 B1 NO305125 B1 NO 305125B1
Authority
NO
Norway
Prior art keywords
alkyl
pharmaceutical compounds
optionally substituted
cycloalkyl
alkyl groups
Prior art date
Application number
NO931917A
Other languages
English (en)
Norwegian (no)
Other versions
NO931917D0 (no
NO931917L (no
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of NO931917D0 publication Critical patent/NO931917D0/no
Publication of NO931917L publication Critical patent/NO931917L/no
Publication of NO305125B1 publication Critical patent/NO305125B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO931917A 1992-05-29 1993-05-26 Farmas°ytiske forbindelser NO305125B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
NO931917D0 NO931917D0 (no) 1993-05-26
NO931917L NO931917L (no) 1993-11-30
NO305125B1 true NO305125B1 (no) 1999-04-06

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931917A NO305125B1 (no) 1992-05-29 1993-05-26 Farmas°ytiske forbindelser

Country Status (21)

Country Link
EP (1) EP0582368B1 (cg-RX-API-DMAC10.html)
JP (1) JP3219541B2 (cg-RX-API-DMAC10.html)
CN (1) CN1043994C (cg-RX-API-DMAC10.html)
AT (1) ATE198891T1 (cg-RX-API-DMAC10.html)
AU (1) AU668159B2 (cg-RX-API-DMAC10.html)
CA (1) CA2097016A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ282783B6 (cg-RX-API-DMAC10.html)
DE (1) DE69329887T2 (cg-RX-API-DMAC10.html)
DK (1) DK0582368T3 (cg-RX-API-DMAC10.html)
ES (1) ES2153373T3 (cg-RX-API-DMAC10.html)
FI (1) FI101538B (cg-RX-API-DMAC10.html)
GR (1) GR3035587T3 (cg-RX-API-DMAC10.html)
HU (1) HU218278B (cg-RX-API-DMAC10.html)
IL (1) IL105827A (cg-RX-API-DMAC10.html)
MX (1) MX9303124A (cg-RX-API-DMAC10.html)
MY (1) MY109943A (cg-RX-API-DMAC10.html)
NO (1) NO305125B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ247703A (cg-RX-API-DMAC10.html)
PT (1) PT582368E (cg-RX-API-DMAC10.html)
RU (1) RU2125574C1 (cg-RX-API-DMAC10.html)
TW (1) TW268005B (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
EA000769B1 (ru) * 1996-03-25 2000-04-24 Эли Лилли Энд Компани Способ лечения при боли, вызванной мигренью
JP2001517202A (ja) * 1996-03-25 2001-10-02 イーライ・リリー・アンド・カンパニー 痛み処置方法
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
CN1146567C (zh) 1996-09-23 2004-04-21 伊莱利利公司 奥氮平二水合物d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
TR199900651T2 (xx) * 1996-09-24 1999-07-21 Eli Lilly And Company Kaplanm�� par�ac�k form�lasyonu.
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
WO2014031587A1 (en) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of olanzipine
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
AU2013305895B2 (en) 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
US9394354B2 (en) 2012-08-21 2016-07-19 Janssen Pharmaceutica Nv Haptens of paliperidone
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
CN108640996A (zh) 2012-08-21 2018-10-12 詹森药业有限公司 帕潘立酮的抗体及其用途
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ.ベー. リスペリドンハプテンへの抗体及びその使用
PL3354751T3 (pl) 2012-08-21 2020-03-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
PT2888257T (pt) 2012-08-21 2017-11-14 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
PL2888593T3 (pl) 2012-08-21 2019-02-28 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
ES2904838T3 (es) 2012-08-21 2022-04-06 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
MA44067A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH569730A5 (cg-RX-API-DMAC10.html) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
DE2641378A1 (de) * 1975-09-24 1977-04-07 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
CH624682A5 (cg-RX-API-DMAC10.html) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
MX9303124A (es) 1993-11-01
IL105827A0 (en) 1993-09-22
AU668159B2 (en) 1996-04-26
HU218278B (en) 2000-07-28
ES2153373T3 (es) 2001-03-01
CN1085903A (zh) 1994-04-27
RU2125574C1 (ru) 1999-01-27
CZ102493A3 (en) 1993-12-15
FI101538B1 (fi) 1998-07-15
JPH0687862A (ja) 1994-03-29
DK0582368T3 (da) 2001-02-05
CZ282783B6 (cs) 1997-10-15
NO931917D0 (no) 1993-05-26
CN1043994C (zh) 1999-07-07
TW268005B (cg-RX-API-DMAC10.html) 1996-01-11
ATE198891T1 (de) 2001-02-15
FI101538B (fi) 1998-07-15
DE69329887D1 (de) 2001-03-01
CA2097016A1 (en) 1993-11-30
EP0582368B1 (en) 2001-01-24
MY109943A (en) 1997-10-31
EP0582368A1 (en) 1994-02-09
DE69329887T2 (de) 2001-05-23
FI932445L (fi) 1993-11-30
JP3219541B2 (ja) 2001-10-15
IL105827A (en) 1997-02-18
NZ247703A (en) 1995-07-26
GR3035587T3 (en) 2001-06-29
PT582368E (pt) 2001-05-31
HU9301579D0 (en) 1993-09-28
AU3980793A (en) 1993-12-02
FI932445A0 (fi) 1993-05-28
HUT66180A (en) 1994-09-28
NO931917L (no) 1993-11-30

Similar Documents

Publication Publication Date Title
NO305125B1 (no) Farmas°ytiske forbindelser
KR930703355A (ko) 항생물질 ge2270 인자의 아미드
DK0674513T3 (da) Retroviral protease-inhiberende forbindelser
ES2054020T3 (es) Compuestos biologicamente activos.
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
ATE198888T1 (de) Antifungizide trisubstituierte tetrahydrofurane
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
SE8404065D0 (sv) Novel biologically active compounds
SE9100920D0 (sv) New active compounds
ATE117989T1 (de) Prostaglandinanaloge enthaltende lipidemulsion.
DK607783D0 (da) Nitroaliphatiske forbindelser
DE3371627D1 (en) Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them
TW275629B (cg-RX-API-DMAC10.html)
DE3867494D1 (de) Fluor enthaltende vitamin-d2-derivate.
ES2037825T3 (es) Uso farmaceutico de tioeteres aromaticos.
GB8823042D0 (en) Organic compounds & their use as pharmaceuticals
DK0826663T3 (da) Alkynylaminosyrederivater og deres anvendelse som farmaceutiske forbindelser

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2002